Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
Nick AndrewsJulia StoweFreja KirsebomSamuel ToffaTim RickeardEileen GallagherCharlotte GowerMeaghan KallNatalie GrovesAnne-Marie O'ConnellDavid SimonsPaula B BlomquistAsad ZaidiSophie NashNurin Iwani Binti Abdul AzizSimon ThelwallGavin DabreraRichard MyersGayatri AmirthalingamSaheer GharbiaJeffrey C BarrettRichard ElsonShamez N LadhaniNeil FergusonMaria ZambonColin N J CampbellKevin E BrownSusan HopkinsMeera ChandMary RamsayJamie Lopez BernalPublished in: The New England journal of medicine (2022)
Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time. (Funded by the U.K. Health Security Agency.).